These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 31642136

  • 1. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
    Shazib MA, Woo SB, Sroussi H, Carvo I, Treister N, Farag A, Schoenfeld J, Haddad R, LeBoeuf N, Villa A.
    Oral Dis; 2020 Mar; 26(2):325-333. PubMed ID: 31642136
    [Abstract] [Full Text] [Related]

  • 2. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 3. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar 01; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 6. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH, Liu Y, Jiang C, Harvey RD.
    Pharmacotherapy; 2020 Feb 21; 40(2):133-141. PubMed ID: 31863604
    [Abstract] [Full Text] [Related]

  • 7. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 21; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 8. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K, Noda T, Ito Y, Hidaka H, Fujimoto S, Takedomi H, Akutagawa T, Sakata Y, Shimamura T, Tominaga N, Yamaguchi D, Fujimoto K.
    Digestion; 2020 Dec 21; 101(1):60-65. PubMed ID: 31801131
    [Abstract] [Full Text] [Related]

  • 9. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 10. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
    Shafqat H, Gourdin T, Sion A.
    Semin Oncol; 2018 Jun 01; 45(3):156-163. PubMed ID: 30348532
    [Abstract] [Full Text] [Related]

  • 11. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K, Nakayama T, Ito A, Sato E, Kitano S.
    BMC Cancer; 2019 Oct 29; 19(1):1019. PubMed ID: 31664934
    [Abstract] [Full Text] [Related]

  • 12. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan 29; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 13. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.
    Eur J Cancer; 2018 Jun 29; 96():91-104. PubMed ID: 29698933
    [Abstract] [Full Text] [Related]

  • 14. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.
    Ann Oncol; 2017 Feb 01; 28(2):368-376. PubMed ID: 27687304
    [Abstract] [Full Text] [Related]

  • 15. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.
    Curr Oncol; 2018 Oct 01; 25(5):e403-e410. PubMed ID: 30464691
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul 01; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 19. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS.
    Aging (Albany NY); 2020 Jun 08; 12(11):10663-10675. PubMed ID: 32516130
    [Abstract] [Full Text] [Related]

  • 20. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, Smit EF.
    Eur J Cancer; 2018 Nov 08; 104():182-187. PubMed ID: 30368069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.